Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
As of August 2025, nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64
Tirzepatide (Mounjaro), the dual GIP/GLP-1 receptor agonist, is licensed by the MHRA for the treatment of type 2 diabetes
This means food stays in the stomach longer, creating a strong and lasting feeling of fullness
Ferri's Clinical Advisor
In practical terms, this means less soreness after heavy strength training or endurance workouts, improved performance in follow-up sessions, and better long-term adaptation to exercise
only use state-licensed pharmacies (see our guide on semaglutide alternatives) A supervised program
US$ 29.74
US$ 25.85
US$ 28.83
US$ 24.00
US$ 21.51
US$ 26.26
US$ 22.76
US$ 24.28
